Morbidity after inguinal sentinel lymph node biopsy and completion lymph node dissection in patients with cutaneous melanoma

作者: M. de Vries , W.G. Vonkeman , R.J. van Ginkel , H.J. Hoekstra

DOI: 10.1016/J.EJSO.2006.05.003

关键词: ErysipelasCutaneous melanomaMedicineLymph nodeDissectionSentinel lymph nodeBiopsySurgerySeromaLymphedema

摘要: Abstract Background Aim of the study was to assess short-term and long-term morbidity after inguinal sentinel lymph node biopsy (SLNB) with or without completion groin dissection (GD) in patients cutaneous melanoma. Methods Between 1995 2003, 127 SLNBs were performed for Sixty-six patients, median age 50 (18–77) years, met inclusion criteria studied. Short-term complications analysed retrospectively, while evaluated using volume measurement range motion lower extremities. Results Fifty-two underwent SLNB alone (SLNB group) 14 tumour-positive (SLNB/GD group). Morbidity alone: wound infections ( n =1), seroma postoperative bleeding erysipelas slight lymphedema 6% =3). SLNB/GD: =4), necrosis 64% =9). There differences between two groups total number p =0.009), abduction =0.011) limitation hip joint. Conclusion Inguinal is accompanied a low complication rate. However, followed by associated an increased risk infection lymphedema.

参考文章(19)
Jeffrey E Gershenwald, William Thompson, Paul F Mansfield, Jeffrey E Lee, Maria I Colome, Chi-hong Tseng, J Jack Lee, Charles M Balch, Douglas S Reintgen, Merrick I Ross, None, Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. Journal of Clinical Oncology. ,vol. 17, pp. 976- 983 ,(1999) , 10.1200/JCO.1999.17.3.976
Peter Beitsch, Charles Balch, Operative morbidity and risk factor assessment in melanoma patients undergoing inguinal lymph node dissection American Journal of Surgery. ,vol. 164, pp. 462- 466 ,(1992) , 10.1016/S0002-9610(05)81181-X
M. W. Kissin, G. Querci Della Rovere, D. Easton, G. Westbury, Risk of lymphoedema following the treatment of breast cancer. British Journal of Surgery. ,vol. 73, pp. 580- 584 ,(2005) , 10.1002/BJS.1800730723
William R. Wrightson, Sandra L. Wong, Michael J. Edwards, Celia Chao, Douglas S. Reintgen, Merrick I. Ross, R. Dirk Noyes, Vicki Viar, Patricia B. Cerrito, Kelly M. McMasters, , Complications associated with sentinel lymph node biopsy for melanoma Annals of Surgical Oncology. ,vol. 10, pp. 676- 680 ,(2003) , 10.1245/ASO.2003.10.001
N. Wasserberg, H. Tulchinsky, J. Schachter, M. Feinmesser, H. Gutman, Sentinel-lymph-node biopsy (SLNB) for melanoma is not complication-free. Ejso. ,vol. 30, pp. 851- 856 ,(2004) , 10.1016/J.EJSO.2004.06.021
A. C. Voogd, J. M. M. A. Ververs, A. J. J. M. Vingerhoets, R. M. H. Roumen, J. W. W. Coebergh, M. A. Crommelin, Lymphoedema and reduced shoulder function as indicators of quality of life after axillary lymph node dissection for invasive breast cancer. British Journal of Surgery. ,vol. 90, pp. 76- 81 ,(2003) , 10.1002/BJS.4010
C. P. Karakousis, D. L. Driscoll, Groin dissection in malignant melanoma BJS. ,vol. 81, pp. 1771- 1774 ,(1994) , 10.1002/BJS.1800811221
Hitoshi Tonouchi, Yukinari Ohmori, Minako Kobayashi, Naomi Konishi, Kouji Tanaka, Yasuhiko Mohri, Hitoshi Mizutani, Masato Kusunoki, Operative Morbidity Associated with Groin Dissections Surgery Today. ,vol. 34, pp. 413- 418 ,(2004) , 10.1007/S00595-003-2738-5
Heimen Schraffordt Koops, M.H.Edwina Doting, Jakob de Vries, A.Ton M.G. Tiebosch, John Th. Plukker, Harold J. Hoekstra, D.Albert Piers, Sentinel node biopsy as a surgical staging method for solid cancers Radiotherapy and Oncology. ,vol. 51, pp. 1- 7 ,(1999) , 10.1016/S0167-8140(99)00024-9
Markwin G. Statius Muller, Paul A. M. van Leeuwen, Elly S. M de Lange-de Klerk, Paul J. van Diest, Rik Pijpers, Charlotte C. Ferwerda, Ronald J. C. L. M. Vuylsteke, Sybren Meijer, The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma. Cancer. ,vol. 91, pp. 2401- 2408 ,(2001) , 10.1002/1097-0142(20010615)91:12<2401::AID-CNCR1274>3.0.CO;2-I